AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
The company is already renowned by many as a giant in the segment.
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
Overview
AbbVie (NYSE:ABBV) was one of the livelier stocks in Monday’s trading session. It was also one of the better-performing equities, gaining more than 6% that day. Much of this was due to a splashy new acquisition that will strengthen its already considerable presence in a lucrative segment of the pharmaceutical market.
Before market open, AbbVie and Apogee Therapeutics (NASDAQ:APGE) announced they had signed a definitive agreement for AbbVie to acquire its peer.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
